Sparrow Pharmaceuticals has filed a notice of an exempt offering of securities to raise $15,251,730.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Sparrow Pharmaceuticals is raising up to $15,251,730.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Jacks played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess – associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrows pipeline is led by SPI-62 in Phase 2 clinical development.
To learn more about Sparrow Pharmaceuticals, visit http://www.sparrowpharma.com/
Contact:
Robert Jacks, Chief Executive Officer
617-465-0328
https://www.linkedin.com/in/robert-jacks-6b5457/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.